2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, Research, AML, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

1670 Efficacy and safety of CPX-351 in combination with gemtuzumab ozogamicin (GO) in newly diagnosed acute myeloid leukemia (AML): Final results of a Phase 1/1b trial

Onyee Chan, MD, Kendra L. Sweet, MD, MS2, Chetasi Talati, MD3, Fatima Tuz Zahra, MBBS4, Lisa Nardelli, BS5, Jatinder K Lamba, PhD6, Jongphil Kim, PhD7, Jinming Song, MD, PhD8, Samuel Benjamin Reynolds, MD9, Rory Shallis, MD10, Zhuoer Xie, MD,MS11, Seongseok Yun, MD, PhD12, Andrew T Kuykendall, MD13, Eric Padron, MD14, Alison Walker, MD15, Rami Komrokji, MD16, Jeffrey Lancet, MD17, David Sallman, MD18
1 Moffitt Cancer Center, Tampa, Florida, United States
2 Moffitt Cancer Center, Tampa, Florida, United States
3 AbbVie, North Chicago, Illinois, United States
4 University of South Florida, Tampa, Florida, United States
5 Moffitt Cancer Center, Tampa, Florida, United States
6 University of Florida, Gainesville, Florida, United States
7 Moffitt Cancer Center, Tampa, Florida, United States
8 Moffitt Cancer Center, Tampa, Florida, United States
9 Moffitt Cancer Center, Tampa, Florida, United States
10 Moffitt Cancer Center, Tampa, Florida, United States
11 Moffitt Cancer Center, Tampa, Florida, United States
12 Moffitt Cancer Center, Tampa, Florida, United States
13 Moffitt Cancer Center, Tampa, Florida, United States
14 Moffitt Cancer Center, Tampa, Florida, United States
15 Moffitt Cancer Center, Tampa, Florida, United States
16 Moffitt Cancer Center, Tampa, Florida, United States
17 Moffitt Cancer Center, Tampa, Florida, United States
18 Moffitt Cancer Center, Tampa, Florida, United States

Introduction: While intensive chemotherapy achieves initial responses in 50-60% of patients (pts) with AML, relapse driven by measurable residual disease (MRD) and persistent leukemic stem cells (LSCs) remains a major challenge. Both CPX-351 (liposomal daunorubicin/cytarabine) and the CD33-directed antibody-drug conjugate gemtuzumab ozogamicin (GO) are active against AML. Given GO's targeted activity against CD33+ blasts and LSCs, we hypothesized that combining CPX-351 with GO would safely produce higher response rates and deeper remissions in pts with newly diagnosed (ND) AML.

Methods: This phase 1/1b trial (NCT05558124) evaluated CPX-351 (daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 on Day 1, 3, 5) combined with GO (Cohort A: 3mg/m2 on Day 1; Cohort B: Day 1, 4; Cohort C: Day 1, 4, 7) for ND CD33+ AML in adults ≤ 70. Pts with known FLT3 mutations were excluded. Expansion cohort eligibility was restricted to ELN 2022 intermediate/adverse risk, prioritizing those with AML-MR (WHO 2022) defining mutations (sMut). Primary objectives were safety and determining MTD/RP2D using a Bayesian optimal interval design. Reinduction of CPX-351 (Day 1, 3) was allowed if indicated by Day 14-24 bone marrow biopsy. Consolidation (up to 4 cycles) consisted of cytarabine (3g/m2 for pts < 60 and 1.5g/m2 for ≥ 60) plus GO on Day 1 (up to 2 cycles).

Results: At the July 2026 data cut-off, enrollment was complete (1/2023-6/2026). Of 28 evaluable pts (escalation: n=18 [A=12, B=6]; expansion: n=10), 21 (75%) were male, with a median age at diagnosis of 64 yrs (range: 22-70). There were 14 pts (50%) with s/t-AML (2 with prior HMA exposure for antecedent myeloid disease). By ELN 2022, 6 (21.4%), 4 (14.3%), and 18 (64.3%) pts had favorable (fav), intermediate (int), and adverse (adv) risk, respectively. There were 17 pts (60.7%) with sMut. The most common mutations included ASXL1 (32.1%), TET2 (28.6%), RUNX1 (25%), SRSF2 (25%), DNMT3A (21.4%), IDH2 (17.9%), NRAS (17.9%), and STAG2 (17.9%). Among responding pts, 18/23 (78.3%) received ≥ 1 consolidation cycle (median: 1, range: 1-4), and none received reinduction.

During dose-escalation, 3 pts experienced DLTs (A=1, B=2) all Grade 4 (G4) cytopenia beyond Day 42 of induction. The Cohort A pt achieved CRi MRD(-) on Day 43 and subsequently proceeded to alloSCT (MRD[-] ongoing at 3 yrs). Of the Cohort B pts, 1 achieved CRi and had alloSCT (MRD[-] ongoing ~2 yrs), and the other with MLFS relapsed 2 months (mos) after induction. For CR/CRi pts, median time to recovery (ANC ≥ 1k or plts ≥ 100k) was 36 days (range: 25-50). When limited to pts from Cohort A/expansion (n=16), recovery shorten to 32.5 days (range: 25-43). Febrile neutropenia (78.6%) was the only G3/4 non-hematologic AE in ≥ 20% of pts. Mortality at 90 days was 0%. The most common G1/2 non-hematologic AEs were maculopapular rash (67.9%), oral mucositis (57.1%), and nausea (50%). There were 8 SAEs attributed to treatment (Cohort A/expansion=7, B=1) including G3: febrile neutropenia (n=4), sepsis (n=2), lung infection (n=1), and thrush (n=1). Thus, Cohort A (Day 1 GO) was established as the RP2D.

Of the 27 response-evaluable pts (Cohort A/expansion=21, B=6), 23 (85.2%) achieved objective response (CR/CRi/MLFS) and 21 (77.8%) achieved CR/CRi (CR: 15 [55.6%], CRi: 6 [22.2%]). Among those with CR/CRi, undetectable MRD by multiparametric flow cytometry was achieved in 85% (17/20) and these pts (n=17) have a median duration of response of 15.2 mos. For pts with fav risk disease, CR/CRi rate was 100% (6/6) and 83.3% (5/6) achieved MRD(-) (3/3 NPM1, 1/2 CBF, and 1/1 CEBPA). For those with int/adv risk, 15/21 (71.4%) achieved CR/CRi with 12/14 (85.7%) MRD(-) and 60% (9/15) proceeded to alloSCT. For pts with sMut, ORR was 15/17 (88.2%) and 13/17 (76.5%) achieved CR/CRi with 10/12 (83.3%) MRD(-). With a median follow up of 19.6 mos, the median OS (mOS) for the entire cohort was NR. In responders with evaluable flow MRD (n=21), mOS was 19.3 mos for MRD(+) (n=3) vs. NR for MRD(-) (n=18; p=0.50). In the sMut subset, mOS was NR regardless of MRD status. Pts who underwent alloSCT (n=10) had significantly longer OS than those who did not (n=18; NR vs. 16.6 mos, p=0.005).

Conclusions: Day 1 GO combined with CPX-351 was identified as the RP2D. The combination achieved undetectable MRD responses in 85% of all pts with favorable outcomes in high-risk subsets, particularly in those with sMut. Together, these data support further evaluation as a frontline strategy.
Onyee Chan, MD: AbbVie, Inc. - Honoraria; Novartis - Honoraria; Remix Therapeutics - Research Funding; Jazz Pharmaceuticals Inc. - Research Funding; AbbVie, Inc. - Research Funding; Kumquat Biosciences, Inc - Research Funding; Cullinan Therapeutics - Research Funding; Daiichi-Sankyo Co. - Research Funding; Takeda - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony)